glucagon receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-05-05 and is reviewed periodically as new material appears.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Studied for metabolic indications |
| Receptor activity | GIP, GLP-1, and glucagon | Single molecule, three targets |
| Development status | Investigational | Not an approved therapy |
| Common synonym | LY3437943 | Development designation |
| Administration route | Subcutaneous injection | As used in clinical studies |
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
In November 2008, the Department of State said that finding the culprit was less important than "to get both sides, particularly the Russians, to live up to their obligations". On 9 September 2008, Chair of the House Foreign Affairs Committee Howard Berman stated in hearing of the United States House Committee on Foreign Affairs that Russia had been provoking Georgia and Saakashvili was compelled to respond to an ethnic cleansing of Georgians in South Ossetia. Berman continued that Russian actions revealed that Russia's real aim was not protection of the Russian citizens. On 9 September 2008, Assistant Secretary of State for European and Eurasian Affairs Daniel Fried said in hearing of the House Committee on Foreign Affairs that Russia had been provoking Georgia and Russia's actual aim was to change the borders of the sovereign nation. Fried further described the events on the night of August 7 and reported that the Georgians had reported the entry of the Russian forces into the Roki Tunnel. Fried said that the US administration clearly "pointed out that use of military force [by Georgia], even in the face of provocations, would lead to a disaster." Fried stated that "one fact is clear—there was no justification for Russia's invasion of Georgia." When Fried was asked why Georgian leadership ignored his clear advice not to resort to military force, he replied that Georgia "had been provoked for a long period of time" by the opposing sides.
Current good manufacturing practices (cGMP) are those conforming to the guidelines recommended by relevant agencies. Those agencies control the authorization and licensing of the manufacture and sale of food and beverages, cosmetics, pharmaceutical products, dietary supplements, and medical devices. These guidelines provide minimum requirements that a manufacturer must meet to assure that their products are consistently high in quality, from batch to batch, for their intended use. The rules that govern each industry may differ significantly; however, the main purpose of GMP is always to prevent harm from occurring to the end user. Additional tenets include ensuring the end product is free from contamination, that it is consistent in its manufacture, that its manufacture has been well documented, that personnel are well trained, and that the product has been checked for quality more than just at the end phase. GMP is typically ensured through the effective use of a quality management system (QMS). Good manufacturing practice, along with good agricultural practice, good laboratory practice and good clinical practice, are overseen by regulatory agencies in the United Kingdom, United States, Canada, various European countries, China, India and other countries.
=== Legal status === In September 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Mycapssa, intended for the treatment of adults with acromegaly. The applicant for this medicinal product is Amryt Pharmaceuticals DAC. Mycapssa was approved for medical use in the European Union in December 2022. In April 2025, the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Oczyesa, intended for the maintenance treatment of adults with acromegaly. The applicant for this medicinal product is Camurus AB. Oczyesa is a hybrid medicine of Sandostatin, which has been authorized in the EU since November 1988. Oczyesa contains the same active substance as Sandostatin but as a different salt and is available at a higher strength and in a different pharmaceutical form. Oczyesa was authorized for medical use in the European Union in June 2025.
=== Produce === Unique to fresh produce cargoes, the cold chain requires to additionally maintain product specific environment parameters which include air quality levels (carbon dioxide, oxygen, humidity and others).
The water then traveled through the channels into sixteen fountains known as the "stairway of fountains", reserving the first water source for the Emperor. This incredible feat supplied the population of Machu Picchu, which varied between 300 and 1000 people when the emperor was present and also helped irrigate water to the farming steppes. The fountains and canal system were built so well that they would, after a few minor repairs, still work today. To go along with the Incas' advanced water supply system, an equally impressive drainage system was built as well. Machu Picchu contains nearly 130 outlets in the center that moved the water out of the city through walls and other structures. The agriculture terraces are a feature of the complicated drainage system; the steppes helped avoid erosion and were built on a slope to aim excess water into channels that ran alongside the stairways. These channels carried the runoff into the main drain, avoiding the main water supply. This carefully planned drainage system shows the Incas' concern and appreciation for clean water. Water engineer Ken Wright and his archaeological team found the emperor’s bathing room complete with a separate drain that carried off his used bath water so it would never re-enter Machu Picchu’s water supply.
Sources: en.wikipedia.org
The FNLA was almost completely wiped out, but UNITA succeeded in retreating deep into the country's wooded highlands, where it continued to mount a determined insurgency. Operation Savannah was widely regarded as a strategic failure. South Africa and the US had committed resources and manpower to the initial objective of preventing a FAPLA victory prior to Angolan independence, which was achieved. But the early successes of Savannah provided the MPLA politburo with a reason to increase the deployment of Cuban troops and Soviet advisers exponentially. The CIA correctly predicted that Cuba and the Soviet Union would continue to support FAPLA at whatever level was necessary to prevail, while South Africa was inclined to withdraw its forces rather than risk incurring heavy casualties. The SADF had suffered between 28 and 35 killed in action. An additional 100 were wounded. Seven South Africans were captured and displayed at Angolan press briefings as living proof of the SADF's involvement. Cuban casualties were known to be much higher; several hundred were killed in engagements with the SADF or UNITA. Twenty Cubans were taken prisoner: 17 by UNITA, and 3 by the South Africans. South Africa's National Party suffered some domestic fallout as a result of Savannah, as Prime Minister Vorster had concealed the operation from the public for fear of alarming the families of national servicemen deployed on Angolan soil. The South African public was shocked to learn of the details, and attempts by the government to cover up the debacle were slated in the local press.
=== Limitations === Limitations to their effectiveness, nevertheless, exist. Sometimes, protection fails for vaccine-related reasons such as failures in vaccine attenuation, vaccination regimens or administration. Failure may also occur for host-related reasons if the host's immune system does not respond adequately or at all. Host-related lack of response occurs in an estimated 2–10% of individuals, due to factors including genetics, immune status, age, health and nutritional status. One type of primary immunodeficiency disorder resulting in genetic failure is X-linked agammaglobulinemia, in which the absence of an enzyme essential for B cell development prevents the host's immune system from generating antibodies to a pathogen. Host–pathogen interactions and responses to infection are dynamic processes involving multiple pathways in the immune system. A host does not develop antibodies instantaneously: while the body's innate immunity may be activated in as little as twelve hours, adaptive immunity can take 1–2 weeks to fully develop. During that time, the host can still become infected. Once antibodies are produced, they may promote immunity in any of several ways, depending on the class of antibodies involved. Their success in clearing or inactivating a pathogen will depend on the amount of antibodies produced and on the extent to which those antibodies are effective at countering the strain of the pathogen involved, since different strains may be differently susceptible to a given immune reaction.
The 2008 Chinese milk scandal was a significant food safety incident in China. The scandal involved Sanlu Group's milk and infant formula along with other food materials and components being adulterated with the chemical melamine, which resulted in kidney stones and other kidney damage in infants. The chemical was used to increase the nitrogen content of diluted milk, giving it the appearance of higher protein content in order to pass quality control testing. 300,000 affected children were identified, among which 54,000 were hospitalized, according to the latest report in January 2009. The deaths of six babies were officially concluded to be related to the contaminated milk. The timeline of the scandal dated back to December 2007, when Sanlu began to receive complaints about kidney stones. An early complaint was made on 20 May 2008, when a mother posted online after she learnt that Sanlu had donated the milk she had been complaining about to the orphans of the 2008 Sichuan earthquake. Also on 20 May, the problem was raised at Sanlu's Board meeting for the first time and they ordered multiple third-party tests. The culprit, melamine, was undetected in the tests until 1 August.
Loop diuretics: furosemide, bumetanide, torsemide, ethacrynic acid Thiazide diuretics: chlorothiazide, hydrochlorothiazide Thiazide-like diuretics: metolazone, indapamide, chlorthalidone Potassium-sparing diuretics: amiloride, triamterene, spironolactone, eplerenone For loop diuretics, thiazide diuretics and thiazide-like diuretics, their common side effects include hypokalemia, hyponatremia, metabolic alkalosis and hyperglycaemia. For potassium-sparing diuretics, its common side effects include hyponatremia, hyperkalemia, metabolic acidosis and sexual dysfunction specifically for spironolactone. The use of diuretics should be avoided in patients with severe dehydration, anuria (absence of urine production). Diuretics are contraindicated in cases of severe electrolyte abnormalities and should not be administered until an electrolyte balance is restored. Special attention should be given to the use of thiazide and loop diuretics as they may exacerbate diabetes and gout.
Sources: en.wikipedia.org
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.
It is characterized in the literature as an investigational agent under clinical study. Approval status depends on jurisdiction, and readers should check current regulatory information rather than assume availability.
The combination is intended to pair appetite-related and glucose-related effects with mechanisms that increase energy expenditure. Whether the combined profile offers advantages over simpler agonists is the subject of ongoing research.
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.